Appl. No. 10/758,513 Attorney Docket No. Serie 6093

Amdt. dated June 20, 2007

Reply to Office Action of March 5, 2007

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1- 15 (cancelled)

Claims 16 - 14 (cancelled)

Claim 42 (currently amended): A method for treating or minimizing, post-ischemic brain cell deterioration in humans comprising the step of administering by inhalation to a human a therapeutically-effective amount of a medicinal composition comprising <u>75 volume percent or less</u> nitrous oxide er nitrous oxide denor, and <u>50 volume percent or less</u> xenon er a xenon denor, at least part of said nitrous oxide er nitrous exide denor and xenon er xenon denor being in gaseous form, thereby treating or minimizing post-ischemic brain cell deterioration in said human.

Claim 43 (canceled)

Claim 44 (previously presented): The method according to Claim 42, wherein said method further comprises adding at least one component selected from the group consisting of oxygen, nitrogen, and argon to said medicinal composition.

Claim 45 (previously presented): The method according to Claim 42, wherein said method comprises adding oxygen and nitrogen to said medicinal composition.

Claim 46 (currently amended): The method according to Claim 43 <u>42</u>, wherein said nitrous oxide or nitrous-oxide denor, and xenon or xenon denor are substantially in gaseous form.

2

Appl. No. 10/758,513 Attorney Docket No. Serie 6093 Amdt. dated June 20, 2007

Reply to Office Action of March 5, 2007

Claim 47 (previously presented): The method according to Claim 42, wherein said postischemic brain cell deterioration is subsequent to a stroke in said human.

Claim 48 (previously presented): The method according to Claim 42, wherein said postischemic brain cell deterioration results in a stroke to said human.

Claims 49-51 (canceled)

Claim 52 (currently amended): The method according to Claim 42, wherein said medicinal composition comprises gaseous xenon and gaseous nitrous oxide <u>are in</u> gaseous form.

Claim 53 (currently amended): The method according to Claim 42, wherein said medicinal composition <u>further</u> comprises from about 19% to about 25% by volume of oxygen.

Claim 54 (currently amended): The method according to Claim 42, wherein said medicinal composition centaining gaseous xenon and gaseous nitrous exide is placed in a pressurized gas container.

Claim 55 (currently amended): A method for treating or minimizing post-ischemic brain cell deterioration in humans comprising the step of administering by inhalation to a human a therapeutically-effective amount of a medicinal composition comprising a mixture of gaseous nitrous oxide and gaseous xenon, thereby treating or minimizing post-ischemic brain cell deterioration in said human, the nitrous oxide being present in an amount of 75 volume percent or less and the xenon being present at a concentration of 50 volume percent or less.

Appl. No. 10/758,513 Attorney Docket No. Serie 6093

Amdt. dated June 20, 2007

Reply to Office Action of March 5, 2007

Claim 56 (previously presented): The method according to Claim 55, wherein the medicinal composition further comprises oxygen.

Claim 57 (canceled)

Claim 58 (currently amended): The method according to Claim 56, wherein said medicinal composition comprises said oxygen is present at a concentration of from about 19% to about 25% by volume of oxygen.

Claim 59 (previously presented): The method according to Claim 55, wherein said postischemic brain cell deterioration is subsequent to a stroke in said human.

Claim 60 (previously presented): The method according to Claim 55, wherein said postischemic brain cell deterioration results in a stroke in said human.

Claim 61 (currently amended): A method for providing a neuro-protective action in the brain of a human comprising the step of administering by inhalation to said human a therapeutically-effective amount of a medicinal composition comprising a mixture of gaseous nitrous oxide <u>at a concentration of 75 volume percent or less</u> and gaseous xenon <u>at a concentration of 50 volume percent or less</u>.

Claim 62 (currently amended): The method according to Claim 60, wherein said medicinal composition comprises up to about 80% by volume of nitrous oxide and less than about 60% by volume of xenon.

Claims 63 - 66 (cancelled)